LOEs continue to buffet AstraZeneca

Share this article:
LOEs continue to buffet AstraZeneca
LOEs continue to buffet AstraZeneca

AstraZeneca sales tumbled for the fourth quarter of 2013 and the year as a whole, falling 4% for the quarter to $6.8 billion, and 8% for the year at $25.7 billion compared to 2012.

Exclusivity losses continued to buffet the company's earnings sheet. Sales of cholesterol medicine Crestor were off 8% for the quarter, at just under $1.5 billion. Declining US prescriptions contributed to the negatives, falling 7% for the quarter. Year-end sales for the prescription medication fell to $5.6 billion, down 8%.

Formulary status changes pushed down market share for diabetes med Onglyza, but fourth quarter sales appeared unchecked, rising 15.8%, to $93 million. Sales rose 17% for the year, to $378 million, compared to $323 million in 2012.

GLP-1 shot Bydureon garnered a slew of new prescriptions during the quarter, boosting sales to $49 million, up from $26 million for the same period last year. The diabetes medication's sales hit $151 million for the year, up from $37 million in 2012. Byetta, also part of the exenatide franchise, saw sales rise almost 15%, to $54 million for the quarter, compared to $47 million in Q4 2012. This increase is not necessarily tied to prescription rates: AstraZeneca said Byetta's total prescriptions fell 35% for the quarter. Year-end sales rose to $206 million, up from $74 million in 2012.

The diabetes franchise got an added boost last week when AstraZeneca took hold of all assets from the now-former collaboration with Bristol-Myers Squibb. The company says around 4,100 former Bristol-Myers employees will be changing the logos on their business cards.

A spokesperson told MM&M by email that 3,400 employees have already made the BMS-to-AZ transition and that the remaining 700, scattered across territories including China, France and Germany, will soon join the crowd. The company said around 1,400 members of the now-former BMS sales force will join the US team.

The collaboration's end gives AstraZeneca full ownership of Onglyza and related products Kombiglyze XR and Kombiglyze, as well as SGLT-2 drug Farxiga, Byetta, Bydureon, metreleptin and Symlin.

The company has already slated 5,050 jobs for elimination under a restricting program it announced in March 2013. These job losses should wrap by 2016. The company said it expects the layoffs will save the company $800 million a year as of 2016.

Seroquel franchise sales fell almost 22% during the quarter, capping a year in which revenue for the antipsychotic slid 39%.

The company expects the next two years will consist of finalizing the pipeline's foundation for growth, with 2017 putting it firmly in a “return to growth” phase.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...